SCHEMBL12438486

SCHEMBL12438486

NC(=O)Cc1ccc(Nc2ncc(Br)c(Nc3cc(C4CC4)n[nH]3)n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 20/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4456951 0.89 IGF1R (0.73) IGF1R
SCHEMBL4466607 0.88 IGF1R (0.70) IGF1R
SCHEMBL4459141 0.87 IGF1R (0.74) IGF1R
SCHEMBL11345387 0.85 IGF1R (0.75) IGF1R
SCHEMBL11339853 0.85 IGF1R (0.68) IGF1R
SCHEMBL11938849 0.85 IGF1R (0.57) IGF1R
SCHEMBL11339784 0.84 IGF1R (0.74) IGF1R
SCHEMBL11345245 0.83 IGF1R (0.69) IGF1R
SCHEMBL4456905 0.83 IGF1R (0.70) IGF1R
SCHEMBL4462586 0.83 IGF1R (0.76) IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1841760-B1 PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHOD OF USE EXELIXIS INC (US) 2011-08-10 EP disclosed
WO-2008127594-A2 COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS, INC. (US) 2008-10-23 WO disclosed